| I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $484.7M | ||||
|
|
||||
| Company | Location | Date | Amt. (M) | Details |
| | ||||
| Affibody AB | Stockholm, Sweden | 10/3 | $28 | Affibody raised $28M from an investment consortium led by Schroder Ventures Life Sciences, HealthCap and Investor Growth Capital; other investors were International Biotechnology Trust plc |
|
| ||||
| Altus Inc. | Cambridge, Mass. | 10/3 | $35 | Altus raised $35M through a private financing with Nomura International plc, U.S. Venture Partners, BankInvest, Clariden Bank and others |
|
| ||||
| Angiogene Inc. | Montreal | 10/11 | C$12 | Angiogene raised US$7.7M; investors were RBC Capital Partners Life Sciences Fund, the Solidarity Fund QFL, Investissement Desjardins and CDP Sofinov |
|
| ||||
| Ardana | Edinburgh, Scotland | 10/31 | #13.3 | Ardana raised US$20M in its first round of financing led by Merlin Biosciences Fund; other investors were MVM Ltd., ABN-AMRO Capital, 3i, Mitsubishi Corp. and Green Highlander |
|
| ||||
| Atto BioScience | Rockville, Md. | 10/29 | $3 | Atto BioScience raised $3M in its first round led by Emerging Technology Partners LLC |
|
| ||||
| Axxima | Martinsried, Germany | 10/22 | $27.3 | Axxima raised $27.3M in a round led by Bear Stearns Health Innoventures LLC |
|
| ||||
| Capsulation | Berlin | 10/2 | DM6 | Capsulation completed its first financing round for US$2.8M; investors were Berlin Seed Capital, Kapitalbeteiligungsgesellschaft des Landes Brandenburg and tbg |
|
| ||||
| Cetek Corp. | Marlborough, Mass. | 10/11 | $14 | Cetek raised $14M in a financing; investors were Stata Ventures Partners, John and Stephen Davis, Gainesborough Investments and James Waters |
|
| ||||
| Chroma | Oxford, UK | 10/25 | #1.5 | Chroma received US$2.15M in seed financing from Abingworth Management Ltd. and Cancer Research Ventures Ltd. |
|
| ||||
| Cyternex Inc. | San Diego | 10/17 | $3.55 | Cyternex raised $3.55M in a Series A financing, which includes four investor groups: Sanderling Ventures, Novartis BioVentures, RCT BioVentures West and Inglewood Ventures |
|
| ||||
| Cytochroma | Kingston, Ontario | 10/29 | C$12 | Cytochroma raised US$7.6M in private equity financing led by The Business Development Bank of Canada; other investors were Novo A/S, VentureLink Capital Corp., GeneChem Technologies Venture Fund LP, Canadian Medical Discoveries Fund and Working Ventures Canadian Fund |
|
| ||||
| DOV | Hackensack, N.J. | 10/17 | $10.4 | DOV raised $10.4M in a Series D convertible preferred stock financing led by Merlin BioMed Private Equity Fund and other investors; Lazard Freres & Co. served as placement agent; Biotechnology Value Fund also is an investor |
|
| ||||
| D-Pharm Ltd. | Rehovot, Israel | 10/16 | $30 | D-Pharm raised $30M in a Series D financing led by Care Capital LLC; other investors were Morgan Stanley Venture Partners, Rho Ventures, Quintiles Transnational Corp., Clal Biotechnology Industries Ltd., the Gemini Group, Denali Ventures and Vertex Group; SG Cowen Securities Corp. was the exclusive placement agent |
|
| ||||
| Discovery | Richmond, Va. | 10/9 | $45 | Discovery raised $45M in a private round led by The Palladin Group; other investors were Schroder Ventures International Life Sciences, International Biotechnology Trust plc, New York Life Bioventures, China Development Industrial Bank, MDS Capital Corp., The NeoMed Fund, Temasek Capital, Singapore BioInnovations and Sanderling BioMedical Ventures |
|
| ||||
| ESBATech | Zurich, Switzerland | 10/30 | N/A | ESBATech closed the first phase of its second round of financing with Lombard Odier & Cie as the lead investor; other investors included Novartis Venture Fund, HBM BioVentures, BSI New Biomedical Frontiers and Peter Ohnemus |
|
| ||||
| Galileo | Montreal | 10/10 | C$16.5 | Galileo raised US$10.5M in equity funding; investors included Investissement Desjardins, BTF, MVI Medical Venture Investments Ltd. and HBM BioVentures |
|
| ||||
| Gene- | San Diego | 10/17 | $22 | GeneFormatics raised $22M in its third round financing; investors included Bruker AXS Inc, Bruker BioSpin Corp. and Bruker Daltonics Inc., as well as Takara Shuzo Co., China Development Industrial Bank, Perseus-Soros BioPharmaceutical Fund LLP, Merrill Lynch Ventures, OrbiMed Advisors LLC, Burrill & Co., GeneChem Inc., Inglewood Ventures and Moss Forest Venture |
|
| ||||
| International | Seattle | 10/4 | $2 | International Therapeutics raised more than $2M in its Series B financing from private investors |
|
| ||||
| Interomex | Vancouver, British Columbia | 10/3 | C$6.3 | Interomex raised US$4M in a financing led by the Business Development Bank of Canada; other investors were Ventures West, T2C2, GeneChem Technologies Venture Fund and Western Technology Seed Investment Fund |
|
| ||||
| Intronn Inc. | Raleigh, N.C. | 10/15 | $7 | Intronn raised $7M in a Series A preferred stock financing led by Proteome Sciences plc; other investors were AEA Investors Inc. and Research Corporation Technologies Inc. |
|
| ||||
| Metabasis | San Diego | 10/23 | $19.2 | Metabasis raised $19.2M in a Series D financing led by The Sprout Group; MPM Capital LP and Interwest Partners also participated |
|
| ||||
| NimbleGen | Madison, Wis. | 10/17 | $1.5 | NimbleGen had a second closing in its Series B financing, raising another $1.5M for a total of $10.5M; investors included Venture Investors Management LLC, Baird Venture Partners, State of Wisconsin Investment Board, Skyline Ventures, Tactics II Investments LLC and the Wisconsin Alumni Research Foundation |
|
| ||||
| Novocell Inc. | Irvine, Calif. | 10/3 | $7 | Novocell raised $7M in its Series B financing; investors were Asset Management, Alloy Ventures, BD Ventures LLC, Pacific Horizon Ventures and the Vertical Group |
|
| ||||
| Protedyne | Windsor, Conn. | 10/15 | $12 | Protedyne closed a $12M private round of financing led by Sprout Group; other investors were Meridian Venture Partners, Long River Ventures and Boston Community Venture Funds |
|
| ||||
| RiboTargets | Cambridge, UK | 10/2 | #32 | RiboTargets raised US$47M in its third-round financing led by JP Morgan Partners and OrbiMed Advisors; other investors were Apax Partners, 3i plc, Advent Venture Partners, NIB Capital NV and Questor |
|
| ||||
| Sagres | Davis, Calif. | 10/5 | $20 | Sagres raised $20M in its second round of financing led by Forward Ventures; other investors were Novartis BioVentures Fund, Burrill Biotechnology Capital Fund and Axiom Venture Partners, as well as Blue Dot Capital Pte Ltd., Walden VC, Jafco Co. Ltd. and China Development Industrial Bank, among others |
|
| ||||
| Sosei Co. | Tokyo | 10/22 | $6.5 | Sosei raised $6.5M in a financing; investors include Nomura Securities, Japan Asia Investment, Tudor Capital, Intec, Nihon Trim, Crescendo Venture Capital, SMBC Capital, Shin Nihon Jitsugyo, Asahi Life Capital and Nissay Capital |
|
| ||||
| Switch | Martinsried, Germany | 10/11 | EUR18 (US | Switch Biotech completed its third round of financing, raising about US$16.5M |
|
| ||||
| Therion | Cambridge, Mass. | 10/30 | $36.5 | Therion raised $36.5M in a private financing led by Hans-Werner Hector; other investors were Sofinov, S.R. One Limited, H&Q Healthcare Investors, H&Q Life Sciences Investors, Loeb Investors and other other private investors |
|
| ||||
| TolerRx | Cambridge, Mass. | 10/23 | $17 | TolerRx raised $17M in a Series B financing led by HealthCare Ventures; other investors were Skyline Ventures, Rho Ventures and Vertex Management |
|
| ||||
| U3 Pharma | Martinsried, Germany | 10/22 | $4.5 | U3 Pharma raised $4.5M in a first round financing involving a group of investors led by Alta Partners and Medicis Ventures |
|
| ||||
| ViaCell | Boston | 10/31 | $15 | ViaCell raised $15M in a private financing led by Genzyme Corp., the Economic Development Board of Singapore and Tullis-Dickerson & Co.; other investors were United Offshore Bank Venture Technology Investments Ltd., Nomura International, The Stephens Group and Zero Stage Capital |
| Note: |
||||
| N/A = Not available or reported. |
||||
|
| ||||
| II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS FROM EXISTING CORPORATE PARTNERS: $45.9M | ||||
|
| ||||
| Company | Partner | Amt. (M) | Triggering Event | Details (Date) |
| | ||||
| 3-Dimen- | Centocor Inc. | $4 | Milestone payment | 3-Dimensional received a $4M milestone payment to develop oral thrombin inhibitors (10/8) |
|
| ||||
| Advanced | Smith & | $5 | Milestone payment | Advanced Tissue Sciences earned a milestone payment for the approval of Dermagraft (10/1) |
|
| ||||
| Aradigm | Novo | $20 | Investment | Novo Nordisk invested $20M in Aradigm as part of a 1998 collaboration to develop the inhaleable-insulin AERx Diabetes Management System (10/25) |
|
| ||||
| Microcide | The R.W. Johnson Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical Inc. (Johnson & Johnson companies) | ND | Milestone payment | Microcide received a milestone payment relating to preclinical research to develop an orally active, novel cephalosporin (10/1) |
|
| ||||
| Neurocrine | GlaxoSmithKline | $15.5 | Milestone payment | GlaxoSmithKline paid Neurocrine $15.5M as part of their agreement for corticotropin-releasing factor receptor antagonists (10/29) |
|
| ||||
| Sangamo | Edwards | $1.4 | Milestone payment | Sangamo received $1.4M for delivering a lead zinc finger DNA-binding protein therapeutic product candidate designed to activate the vascular endothelial growth factor gene (10/18) |
| Notes: | ||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
| ND = Not disclosed | ||||
